Latest Recruitment News

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Cavalier Resources is advancing site preparation, contractor negotiations and recruitment at its Crawford Gold Project, but its financing remains unfinished after Javelin Global Commodities’ exclusivity period expired. Shareholders have also approved a A$60,000 share subscription by interim CEO Daniel Tuffin.

Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.

Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.

Pantoro Gold says Norseman has produced 19,130 ounces quarter-to-date, keeping FY2027 output within reach of its 90,000 to 105,000-ounce target. A second open pit is now delivering ore while Racetrack drilling continues to build a potential future mine source.

Innovaero Technologies is seeking A$40 million through a proposed ASX listing to advance its OWL loitering munition program and expand manufacturing capacity. The replacement prospectus also makes clear that the company remains loss-making and heavily dependent on the Department of Defence converting development work into production orders.

South Port New Zealand delivered record FY26 earnings and cargo volumes, lifting its annual dividend to 29.0 cents per share. The next test is whether its core Southland trade can hold up as one-off wind farm cargo disappears and the port enters a leadership transition.

Data#3 delivered another record year, lifting gross sales 12.7% to $3.4 billion and profit before tax 14% to $78.8 million. The result came with a higher dividend and stronger recurring sales, but weaker Services performance, lower margins and softer operating cash flow leave FY27 with a clear execution challenge.

Epiminder has enrolled the 75th patient in its DETECT study, meeting its September target as the US site network expands to 21 centres. The company expects to reach 100 enrolments in November and remains focused on completing the 210-patient study by the end of the first half of calendar 2027.

HiTech Group has secured a $4 million placement to fund working capital after completing its acquisition of selected Hudson assets. The deal creates a larger national recruitment platform, but also leaves the company managing higher payroll demands, new debt and unfinished customer novations.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Prescient Therapeutics has extended its Share Purchase Plan by three days after shareholders reported delays receiving application documents. The revised timetable places the offer’s results announcement just ahead of a planned briefing on the company’s PTX-100 development program.